Upcoming NHLBI ICTR Webinar, September 20, 2018

In our first public National Heart, Lung, and Blood Institute (NHLBI) Innovative Clinical Trials Resource (ICTR) webinar, Berry Consultants' Kert Viele will review the value of the main components of a gold standard randomized clinical trial and review a variety of innovative trial techniques in comparison to the gold standard. For each innovative technique, he will discuss the potential advantage and disadvantages of the method in comparison to a standard clinical trial, illustrating the tradeoffs to be considered when adopting innovative clinical trials. Innovative trial designs to be discussed include flexible sample sizes, enrichment, the utilization of historical information, multiple arm and multiple domain trials, and novel endpoints.  This public webinar titled, "An Introduction and Overview of Innovative Trial Design, is September 20, 2018 from 3pm – 4pm ET.   Additional information and the webinar's direct link can be found here

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and